• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Merck Announces Third-Quarter 2024 Financial Results

    10/31/24 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRK alert in real time by email
    • Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7%
      • KEYTRUDA Sales Grew 17% to $7.4 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21%
      • WINREVAIR Sales Were $149 Million; U.S. Launch of WINREVAIR Gaining Momentum; Received Approval in the EU
      • Animal Health Sales Grew 6% to $1.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 11%
    • GAAP EPS Was $1.24; Non-GAAP EPS Was $1.57; GAAP and Non-GAAP EPS Include a Net Charge of $0.79 per Share Related to Certain Business Development Transactions
    • Achieved Significant Milestones in Vaccine Programs
      • CAPVAXIVE Recommended by the CDC's ACIP for Pneumococcal Vaccination in Adults 50 Years of Age and Older
      • Presented Positive Results From Clinical Studies Evaluating Clesrovimab (MK-1654), an Investigational RSV Preventative Monoclonal Antibody for Infants Entering Their First RSV Season
    • Data Presented for Four Approved Medicines and Six Pipeline Candidates in More Than 20 Types of Cancer at ESMO Congress 2024, Including Overall Survival Data From KEYNOTE-522 and KEYNOTE-A18
    • Completed Acquisition of Investigational B-Cell Depletion Therapy, CN201 (MK-1045), From Curon Biopharmaceutical
    • Full-Year 2024 Financial Outlook
      • Narrows Expected Worldwide Sales Range To Be Between $63.6 Billion and $64.1 Billion
      • Now Expects Non-GAAP EPS To Be Between $7.72 and $7.77; Outlook Reflects a Net Negative Impact of $0.24 per Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi Sankyo

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2024.

    "Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond," said Robert M. Davis, chairman and chief executive officer, Merck. "Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a more diversified portfolio to drive growth. I continue to remain confident in the strength of our business and our ability to execute, and I want to thank our colleagues across the globe for their focus and commitment as we work to create lasting value for patients, shareholders and all our stakeholders."

    Financial Summary

    $ in millions, except EPS amounts

    Third Quarter

    2024 

    2023 

    Change 

    Change Ex- 

    Exchange 

    Sales

    $16,657 

    $15,962 

    4% 

    7% 

    GAAP net income1

    3,157 

    4,745 

    -33% 

    -30% 

    Non-GAAP net income that excludes certain items1,2*

    3,985 

    5,427 

    -27% 

    -23% 

    GAAP EPS

    1.24 

    1.86 

    -33% 

    -30% 

    Non-GAAP EPS that excludes certain items2*

    1.57 

    2.13 

    -26% 

    -23% 

    *Refer to table on page 7.

    In the third quarter of 2024, total worldwide sales were $16.7 billion, an increase of 4% compared with the third quarter of 2023; excluding the impact of foreign exchange, growth was 7%. Sales growth in the third quarter of 2024 was primarily due to increased usage of KEYTRUDA globally, contributions from new launches, including WINREVAIR and CAPVAXIVE, and strong growth in Merck's Animal Health business. Revenue growth in the third quarter of 2024 was partially offset by lower sales of JANUVIA and JANUMET, lower combined sales of GARDASIL/GARDASIL 9 and lower sales of LAGEVRIO. Third-quarter GARDASIL/GARDASIL 9 sales declined year-over-year due to reduced demand in China; outside of China, the company achieved double-digit sales growth for GARDASIL/GARDASIL 9 in almost every major region globally.

    For the third quarter of 2024, Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming dilution was $1.24 and non-GAAP EPS was $1.57. The declines in GAAP and Non-GAAP EPS in the third quarter of 2024 versus the prior year were largely due to a net charge of $0.79 per share in the aggregate for the acquisition of Eyebiotech Limited (EyeBio) and a related development milestone, the acquisition of CN201 (now known as MK-1045) from Curon Biopharmaceutical (Curon), as well as a payment received from Daiichi Sankyo related to the expansion of the existing development and commercialization agreement. There were no significant business development transaction charges in the third quarter of 2023.

    Non-GAAP EPS in both periods excludes acquisition- and divestiture-related costs, costs related to restructuring programs, as well as income and losses from investments in equity securities.

    Year-to-date results can be found in the attached tables.

    Third-Quarter Sales Performance

    The following table reflects sales of the company's top products and significant performance drivers.

     

    Third Quarter

    $ in millions

    2024 

    2023 

    Change

    Change

    Ex-

    Exchange

    Commentary

    Total Sales

    $16,657 

    $15,962 

    4% 

    7% 

    Approximately 2 percentage points of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

    Pharmaceutical

    14,943 

    14,263 

    5% 

    8% 

    Increase driven by growth in oncology and cardiovascular, partially offset by declines in diabetes, vaccines and virology.

    KEYTRUDA

    7,429 

    6,338 

    17% 

    21% 

    Growth driven by increased global uptake in earlier-stage indications, including triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC), as well as continued strong global demand from metastatic indications. Approximately 3 percentage points of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases.

    GARDASIL/GARDASIL 9

    2,306 

    2,585 

    -11% 

    -10% 

    Decline primarily due to lower demand in China compared with prior year, partially offset by higher sales in the U.S., driven by public-sector buying patterns, higher pricing and demand, as well as higher demand in most international regions.

    PROQUAD, M-M-R II and VARIVAX

    703 

    713 

    -1% 

    -1% 

    Decline primarily due to timing of shipments and lower tenders in Latin America, largely offset by higher demand in certain international markets.

    JANUVIA/JANUMET

    482 

    835 

    -42% 

    -38% 

    Decline primarily due to lower pricing in the U.S., as well as ongoing generic competition in many international markets.

    BRIDION

    420 

    424 

    -1% 

    0% 

    Relatively flat compared with prior year due to generic competition in certain international markets, particularly in Europe and Japan, largely offset by higher demand and pricing in the U.S.

    LAGEVRIO

    383 

    640 

    -40% 

    -36% 

    Decline primarily due to lower demand in Japan, partially offset by uptake from commercial launch in the U.S.

    Lynparza*

    337 

    299 

    13% 

    13% 

    Growth primarily due to higher global demand.

    Lenvima*

    251

    260 

    -3% 

    -4% 

    Decline primarily due to timing of shipments in China in the prior year, partially offset by higher demand in the U.S.

    VAXNEUVANCE

    239 

    214 

    12% 

    13% 

    Growth largely driven by continued uptake from launches in Europe and Japan, partially offset by lower demand in the U.S. due to competition.

    PREVYMIS

    208 

    157 

    32% 

    36% 

    Growth primarily due to higher global demand, particularly in the U.S.

    ROTATEQ

    193 

    156 

    24% 

    25% 

    Growth primarily due to public-sector buying patterns in the U.S. and timing of shipments in China.

    WINREVAIR

    149 

    - 

    - 

    - 

    Represents continued uptake since launch in the U.S. in the second quarter.

    WELIREG

    139 

    54 

    156% 

    157% 

    Growth primarily driven by higher demand in the U.S., largely attributable to ongoing uptake of a new indication.

    Animal Health

    1,487 

    1,400 

    6% 

    11% 

    Growth primarily driven by higher demand and pricing for both Companion Animal and Livestock product portfolios, as well as sales related to July 2024 acquisition of Elanco aqua business. Approximately 2 percentage points of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases.

    Livestock

    886 

    874 

    1% 

    7% 

    Growth primarily driven by higher pricing and higher demand for poultry and swine products, as well as sales related to acquisition of Elanco aqua business.

    Companion Animal

    601 

    526 

    14% 

    17% 

    Growth primarily driven by uptake from new product launches, including the injectable formulation of BRAVECTO in certain international markets, as well as higher pricing across product portfolio. Sales of BRAVECTO were $266 million and $235 million in current and prior year quarters, respectively, which represented growth of 13%, or 16% excluding impact of foreign exchange.

    Other Revenues**

    227 

    299

    -24% 

    -22% 

    Decline primarily due to lower payments received for out-licensing arrangements and lower royalty income.

    *Alliance revenue for this product represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs.

    **Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities.

     

    Third-Quarter Expense, EPS and Related Information

    The table below presents selected expense information.

    $ in millions

    GAAP

    Acquisition-

    and

    Divestiture-

    Related

    Costs3

    Restructuring

    Costs

    (Income)

    Loss From

    Investments

    in Equity

    Securities

    Non-

    GAAP2

    Third Quarter 2024

    Cost of sales

    $4,080 

    $639 

    $192 

    $- 

    $3,249 

    Selling, general and administrative

    2,731 

    43 

    31 

    - 

    2,657 

    Research and development

    5,862 

    24 

    - 

    - 

     5,838 

    Restructuring costs

    56 

    - 

    56 

    - 

    - 

    Other (income) expense, net

    (162) 

    (27) 

    - 

    58 

    (193) 

     

     

     

     

     

     

    Third Quarter 2023

     

     

     

     

    Cost of sales

    $4,264 

    $552 

    $33 

    $- 

    $3,679 

    Selling, general and administrative

    2,519 

    17 

    40 

    - 

    2,462 

    Research and development

    3,307 

    10 

    - 

    - 

    3,297 

    Restructuring costs

    126 

    - 

    126 

    - 

    - 

    Other (income) expense, net

    126 

    (24) 

    - 

    17 

    133 

    GAAP Expense, EPS and Related Information

    Gross margin was 75.5% for the third quarter of 2024 compared with 73.3% for the third quarter of 2023. The increase was primarily due to the favorable impact of product mix (including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9), partially offset by higher restructuring costs (primarily reflecting asset impairment charges), as well as higher amortization of intangible assets.

    Selling, general and administrative (SG&A) expenses were $2.7 billion in the third quarter of 2024, an increase of 8% compared with the third quarter of 2023. The increase was primarily due to higher administrative, promotional, selling, and acquisition-related costs, partially offset by the favorable impact of foreign exchange.

    Research and development (R&D) expenses were $5.9 billion in the third quarter of 2024, an increase of 77% compared with the third quarter of 2023. The increase was primarily due to a charge of $1.35 billion for the acquisition of EyeBio and a $100 million charge for a related development milestone, as well as a charge of $750 million to acquire CN201 (MK-1045) from Curon. The increase in R&D expenses was also driven by higher compensation and benefit costs, as well as higher clinical development spending. The increase in R&D expenses was partially offset by the favorable impact of foreign exchange.

    Other (income) expense, net, was $162 million of income in the third quarter of 2024 compared with $126 million of expense in the third quarter of 2023. The favorability was primarily due to a $170 million payment received from Daiichi Sankyo related to the expansion of the existing development and commercialization agreement, lower exchange losses and lower net interest expense.

    The effective tax rate of 22.7% for the third quarter of 2024 includes a 7.2 percentage point combined unfavorable impact related to the EyeBio and Curon transactions.

    GAAP EPS was $1.24 for the third quarter of 2024 compared with $1.86 for the third quarter of 2023. GAAP EPS in the third quarter of 2024 includes a net charge of $0.79 per share in the aggregate for the EyeBio, Curon and Daiichi Sankyo transactions. There were no significant business development transaction charges in the third quarter of 2023.

    Non-GAAP Expense, EPS and Related Information

    Non-GAAP gross margin was 80.5% for the third quarter of 2024 compared with 77.0% for the third quarter of 2023. The increase was primarily due to the favorable impact of product mix (including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9).

    Non-GAAP SG&A expenses were $2.7 billion in the third quarter of 2024, an increase of 8% compared with the third quarter of 2023. The increase was primarily due to higher administrative, promotional and selling costs, partially offset by the favorable impact of foreign exchange.

    Non-GAAP R&D expenses were $5.8 billion in the third quarter of 2024, an increase of 77% compared with the third quarter of 2023. The increase was primarily due to a charge of $1.35 billion for the acquisition of EyeBio and a $100 million charge for a related development milestone, as well as a charge of $750 million to acquire CN201 (MK-1045) from Curon. The increase in R&D expenses was also driven by higher compensation and benefit costs, as well as higher clinical development spending. The increase in R&D expenses was partially offset by the favorable impact of foreign exchange.

    Non-GAAP other (income) expense, net, was $193 million of income in the third quarter of 2024 compared with $133 million of expense in the third quarter of 2023. The favorability was primarily due to a $170 million payment received from Daiichi Sankyo related to the expansion of the existing development and commercialization agreement, lower exchange losses and lower net interest expense.

    The non-GAAP effective tax rate of 21.9% for the third quarter of 2024 includes a 6.0 percentage point combined unfavorable impact related to the EyeBio and Curon transactions.

    Non-GAAP EPS was $1.57 for the third quarter of 2024 compared with $2.13 for the third quarter of 2023. Non-GAAP EPS in the third quarter of 2024 includes a net charge of $0.79 per share in the aggregate for the EyeBio, Curon and Daiichi Sankyo transactions. There were no significant business development transaction charges in the third quarter of 2023.

    A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows.

    Third Quarter

    $ in millions, except EPS amounts

    2024 

    2023 

    EPS

     

     

    GAAP EPS

    $1.24 

    $1.86 

    Difference

    0.33 

    0.27 

    Non-GAAP EPS that excludes items listed below2

    $1.57 

    $2.13 

     

     

     

    Net Income

     

     

    GAAP net income1

    $3,157 

    $4,745 

    Difference

    828 

    682 

    Non-GAAP net income that excludes items listed below1,2

    $3,985 

    $5,427 

     

     

     

    Excluded Items:

     

     

    Acquisition- and divestiture-related costs3

    $679 

    $555 

    Restructuring costs

    279 

    199 

    Loss from investments in equity securities

    58 

    17 

    Decrease to net income

    1,016 

    771 

    Estimated income tax (benefit) expense

    (188) 

    (89) 

    Decrease to net income

    $828 

    $682 

    Pipeline and Portfolio Highlights

    In the third quarter, Merck continued to develop and augment its strong, diverse pipeline and achieve key regulatory and clinical milestones.

    In cardiovascular disease, Merck continued to build on positive momentum in its U.S. launch of WINREVAIR. As of the end of September 2024, more than 3,700 patients have been prescribed WINREVAIR. The company also received the European Commission's (EC) approval of WINREVAIR, in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of adult patients with PAH with World Health Organization (WHO) functional Class II to III. WINREVAIR is the first activin signaling inhibitor approved for the treatment of PAH in Europe. WINREVAIR has launched in Germany and Merck is working to obtain reimbursement for WINREVAIR in other countries in the EU, which should occur in most other major European markets in the second half of 2025.

    In oncology, Merck continued to reinforce its leadership in women's and earlier stages of cancers and demonstrate progress in its research pipeline. At the European Society for Medical Oncology (ESMO) Congress 2024, three of the company's data presentations were highlighted during Presidential Symposium sessions. These included overall survival (OS) data from the Phase 3 KEYNOTE-522 trial in high-risk, early-stage TNBC and from the Phase 3 KEYNOTE-A18 trial (also known as ENGOT-cx11/GOG-3047) in high-risk, locally advanced cervical cancer. In addition, new positive data on investigational candidates from Merck's pipeline were presented, including for patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate (ADC) being developed in collaboration with Daiichi Sankyo, and for sacituzumab tirumotecan (sac-TMT), an anti-TROP2 ADC being developed in collaboration with Kelun-Biotech.

    The company also achieved several regulatory milestones, including new approvals for KEYTRUDA-based regimens in the U.S., Europe and Japan. In addition, Merck recently announced top-line results from the KEYNOTE-689 trial, which marks the first positive trial in two decades for patients with resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

    In vaccines, the CDC's Advisory Committee on Immunization Practices (ACIP) voted in October 2024 to recommend CAPVAXIVE for individuals 50 to 64 years of age. This decision expanded upon the initial unanimous recommendation in June 2024 for use of CAPVAXIVE in adults age 65 and older, among other cohorts.

    At IDWeek 2024, Merck presented positive results from the Phase 2b/3 trial of clesrovimab (MK-1654), an investigational respiratory syncytial virus (RSV) preventative monoclonal antibody for infants. These results support the potential for clesrovimab to become the first and only single-dose immunization designed to protect infants with the same dose, regardless of weight, for the duration of their first RSV season (six months).

    In immunology, long-term efficacy and safety data for tulisokibart (MK-7240), an investigational humanized monoclonal antibody directed to a novel target, tumor necrosis factor (TNF)-like cytokine 1A (TL1A), from the Phase 2 ARTEMIS-UC and APOLLO-CD studies in ulcerative colitis (UC) and Crohn's disease (CD), were presented at the United European Gastroenterology (UEG) Week 2024 Congress. Both studies showed that, at week 50, maintenance of treatment efficacy was generally observed in 12-week induction responders. Phase 3 studies in UC and CD are ongoing.

    In addition, Merck continued to expand and diversify its pipeline by securing strategic business development opportunities. Merck completed its acquisition of CN201 (MK-1045), a next-generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, from Curon. Merck also announced the expansion of the global development and commercialization agreement with Daiichi Sankyo to include MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager. The companies are planning to evaluate MK-6070 in combination with ifinatamab deruxtecan (I-DXd) in certain patients with small cell lung cancer (SCLC), as well as other potential combinations.

    Notable recent news releases on Merck's pipeline and portfolio are provided in the table that follows.

    Oncology

    FDA Approved KEYTRUDA Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma, Based on Results From Phase 3 KEYNOTE-483/CCTG IND.227 Trial

    (Read Announcement)

    EC Approved KEYTRUDA Plus Padcev as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults, Based on Results From Phase 3 KEYNOTE-A39/EV-302 Trial

    (Read Announcement)

    KEYTRUDA Received 30th Approval From EC With Two New Indications in Gynecologic Cancers, Based on Results From Phase 3 KEYNOTE-868/NRG-GY018 and KEYNOTE-A18 Trials

    (Read Announcement)

    KEYTRUDA Received New Approvals in Japan for Certain Patients With NSCLC, Based on Results From Phase 3 KEYNOTE-671 Trial, and for Radically Unresectable Urothelial Carcinoma, Based on Results From Phase 3 KEYNOTE-A39/EV-302 and Phase 2 KEYNOTE-052 Trials

    (Read Announcement)

    KEYTRUDA Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk, Early-Stage TNBC, Based on Results From Phase 3 KEYNOTE-522

    (Read Announcement)

    KEYTRUDA Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer, Based on Results From Phase 3 KEYNOTE-A18/ENGOT-cx11/GOG-3047 Trial

    (Read Announcement)

    KEYTRUDA Ten-Year Data Demonstrated Sustained OS Benefit Versus Ipilimumab in Advanced Melanoma, Based on Results From Phase 3 KEYNOTE-006 Trial

    (Read Announcement)

    KEYTRUDA Plus Lenvima in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma, Based on Results From Phase 3 LEAP-012 Trial

    (Read Announcement)

    KEYTRUDA Plus Trastuzumab and Chemotherapy Significantly Improved OS Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma, Based on Results From Phase 3 KEYNOTE-811 Trial

    (Read Announcement)

    KEYTRUDA Met Primary Endpoint of Event-Free Survival as Perioperative Treatment Regimen in Patients With Resected, LA-HNSCC, Based on Results From Phase 3 KEYNOTE-689 Trial

    (Read Announcement)

    Patritumab Deruxtecan (HER3-DXd) Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC, Based on Results From Phase 3 HERTHENA-Lung02 Trial

    (Read Announcement)

    Ifinatamab Deruxtecan Continued to Demonstrate Promising Objective Response Rates in Patients With Extensive-Stage SCLC, Based on Results From Phase 2 IDeate-Lung01 Trial

    (Read Announcement)

    Merck and Moderna Initiated Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination With KEYTRUDA After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of NSCLC

    (Read Announcement)

    Merck Initiated Phase 3 Shorespan-007 Trial for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia

    (Read Announcement)

    Merck and Daiichi Sankyo Initiated Phase 3 IDeate-Lung02 Trial of Ifinatamab Deruxtecan in Patients With Relapsed SCLC

    (Read Announcement)

    Merck and Exelixis Signed Clinical Development Collaboration To Evaluate Investigational Zanzalintinib in Combination With KEYTRUDA in Head and Neck Cancer and in Combination With WELIREG in RCC

    (Read Announcement)

    Vaccines

    Clesrovimab (MK-1654), an Investigational RSV Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-Term Infants, Based on Results From Phase 2b/3 MK-1654-004 Trial

    (Read Announcement)

    CDC's ACIP Recommended CAPVAXIVE for Pneumococcal Vaccination in Adults 50 Years of Age and Older

    (Read Announcement)

    CAPVAXIVE Demonstrated Positive Immune Responses in Adults With Increased Risk for Pneumococcal Disease, Based on Results From Phase 3 STRIDE-8 Trial

    (Read Announcement)

    Merck Announced Positive Top-line Results From Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL 9 in Japanese Males

    (Read Announcement)

    Cardiovascular

    EC Approved WINREVAIR in Combination With Other PAH Therapies for the Treatment of PAH in Adult Patients With Functional Class II-III, Based on Results From Phase 3 STELLAR Trial

    (Read Announcement)

    Immunology

    Merck Presented New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024

    (Read Announcement)

    Infectious Diseases

    Merck and Gilead Announced Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir (MK-8591D) Maintained Viral Suppression in Adults at Week 48

    (Read Announcement)

    Ophthalmology

    Merck and EyeBio Initiated Phase 2b/3 Clinical Trial for MK-3000 for the Treatment of Diabetic Macular Edema

    (Read Announcement)

    Sustainability Highlights

    Merck issued its 2023/2024 Impact Report, reaffirming its commitment to operating responsibly and enabling broad access to its products. The report noted how the company reached more than 550 million people around the world with its medicines and vaccines through commercial channels, clinical trials, voluntary licensing and product donations.

    Full-Year 2024 Financial Outlook

    The following table summarizes the company's full-year financial outlook.

     

    Full Year 2024

     

    Updated

    Prior

    Sales*

    $63.6 to $64.1 billion

    $63.4 to $64.4 billion

    Non-GAAP Gross margin2

    Approximately 81%

    Approximately 81%

    Non-GAAP Operating expenses2**

    $27.8 to $28.3 billion

    $26.8 to $27.6 billion

    Non-GAAP Other (income) expense, net2

    Approximately $100 million expense

    Approximately $350 million expense

    Non-GAAP Effective tax rate2

    16.0% to 17.0%

    15.5% to 16.5%

    Non-GAAP EPS2***

    $7.72 to $7.77

    $7.94 to $8.04

    Share count (assuming dilution)

    Approximately 2.54 billion

    Approximately 2.54 billion

    *The company does not have any non-GAAP adjustments to sales.

    **Includes one-time R&D charges of $656 million for Harpoon Therapeutics, Inc. (Harpoon) acquisition, $1.45 billion for EyeBio acquisition and related development milestone payment, and $750 million for acquisition of CN201 (MK-1045) from Curon. Outlook does not assume any additional significant potential business development transactions.

    ***Includes net one-time charge of $1.05 per share in aggregate for the Harpoon, EyeBio and Curon transactions, and the cash payment received from Daiichi Sankyo.

    Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot predict with reasonable certainty the amounts necessary for such a reconciliation, including intangible asset impairment charges, legal settlements, and gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds, without unreasonable effort. These items are inherently difficult to forecast and could have a significant impact on the company's future GAAP results.

    Merck continues to experience strong growth, including from KEYTRUDA, new product launches and Animal Health. As a result, Merck is narrowing the range of its full-year sales outlook.

    Merck now expects its full-year sales to be between $63.6 billion and $64.1 billion, including a negative impact of foreign exchange of approximately 3 percentage points, at mid-October 2024 exchange rates. Approximately 2 percentage points of the negative impact of foreign exchange is due to the devaluation of the Argentine peso, which is being largely offset by inflation-related price increases, consistent with practice in that market.

    Merck now expects its full-year non-GAAP effective income tax rate to be between 16.0% and 17.0%, which includes an unfavorable impact related to the one-time charge associated with the acquisition of CN201 (MK-1045) from Curon.

    Merck now expects its full-year non-GAAP EPS to be between $7.72 and $7.77. The outlook includes a negative impact of foreign exchange of approximately $0.30 per share. The negative impact of foreign exchange is primarily due to the devaluation of the Argentine peso, which is being largely offset by inflation-related price increases, consistent with practice in that market. This revised non-GAAP EPS range reflects a net charge of $0.24 per share for the following items not previously included in the outlook:

    • The acquisition of CN201 (MK-1045) from Curon.
    • Payment received from Daiichi Sankyo related to the expansion of the existing development and commercialization agreement.

    Consistent with past practice, the financial outlook does not assume additional significant potential business development transactions.

    Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to restructuring programs, income and losses from investments in equity securities, as well as a tax benefit in 2024 due to a reduction in reserves for unrecognized income tax benefits, resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.

    Earnings Conference Call

    Investors, journalists and the general public may access a live audio webcast of the earnings conference call on Thursday, October 31, at 9 a.m. ET via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, and slides highlighting the results, will be available at www.merck.com.

    All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590.

    About Merck

    At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

    This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

    Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

    The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

    Appendix

    Generic product names are provided below.

    Pharmaceutical

    BRIDION (sugammadex)

    CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)

    GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)

    GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)

    JANUMET (sitagliptin and metformin HCl)

    JANUVIA (sitagliptin)

    KEYTRUDA (pembrolizumab)

    LAGEVRIO (molnupiravir)

    Lenvima (lenvatinib)

    Lynparza (olaparib)

    M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)

    PREVYMIS (letermovir)

    PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

    ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent)

    VARIVAX (Varicella Virus Vaccine Live)

    VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)

    VERQUVO (vericiguat)

    WELIREG (belzutifan)

    WINREVAIR (sotatercept-csrk)

    Animal Health

    BRAVECTO (fluralaner)

    _________________________________

    1

    Net income attributable to Merck & Co., Inc.

    2

    Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management's compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release.

    3

    Reflects expenses related to acquisitions of businesses, including the amortization of intangible assets, intangible asset impairment charges and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well as amortization of intangible assets related to collaborations and licensing arrangements.

    MERCK & CO., INC.
    CONSOLIDATED STATEMENT OF INCOME - GAAP
    (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
    (UNAUDITED)
    Table 1
     
    GAAP % Change GAAP % Change
     

     

    3Q24

     

     

    3Q23

     

    Sep YTD 2024 Sep YTD 2023
     
     
    Sales

    $

    16,657

     

    $

    15,962

     

    4

    %

    $

    48,544

     

    $

    45,485

     

    7

    %

     
    Costs, Expenses and Other
    Cost of sales

     

    4,080

     

     

    4,264

     

    -4

    %

     

    11,365

     

     

    12,214

     

    -7

    %

    Selling, general and administrative

     

    2,731

     

     

    2,519

     

    8

    %

     

    7,952

     

     

    7,700

     

    3

    %

    Research and development

     

    5,862

     

     

    3,307

     

    77

    %

     

    13,354

     

     

    20,904

     

    -36

    %

    Restructuring costs

     

    56

     

     

    126

     

    -56

    %

     

    258

     

     

    344

     

    -25

    %

    Other (income) expense, net

     

    (162

    )

     

    126

     

    *

     

    (151

    )

     

    388

     

    *
    Income Before Taxes

     

    4,090

     

     

    5,620

     

    -27

    %

     

    15,766

     

     

    3,935

     

    *
    Taxes on Income

     

    929

     

     

    870

     

     

    2,377

     

     

    2,332

     

    Net Income

     

    3,161

     

     

    4,750

     

    -33

    %

     

    13,389

     

     

    1,603

     

    *
    Less: Net Income Attributable to Noncontrolling Interests

     

    4

     

     

    5

     

     

    15

     

     

    12

     

    Net Income Attributable to Merck & Co., Inc.

    $

    3,157

     

    $

    4,745

     

    -33

    %

    $

    13,374

     

    $

    1,591

     

    *
     
    Earnings per Common Share Assuming Dilution

    $

    1.24

     

    $

    1.86

     

    -33

    %

    $

    5.26

     

    $

    0.62

     

    *
     
    Average Shares Outstanding Assuming Dilution

     

    2,541

     

     

    2,546

     

     

    2,543

     

     

    2,549

     

    Tax Rate

     

    22.7

    %

     

    15.5

    %

     

    15.1

    %

     

    59.3

    %

     
     
    * 100% or greater
    MERCK & CO., INC.
    THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 GAAP TO NON-GAAP RECONCILIATION
    (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
    (UNAUDITED)
    Table 2a
     
     
    GAAP Acquisition and Divestiture-Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal Non-GAAP
     
    Third Quarter
    Cost of sales

    $

    4,080

     

    639

     

    192

     

    831

     

    $

    3,249

     

    Selling, general and administrative

     

    2,731

     

    43

     

    31

     

    74

     

     

    2,657

     

    Research and development

     

    5,862

     

    24

     

    24

     

     

    5,838

     

    Restructuring costs

     

    56

     

    56

     

    56

     

     

    –

     

    Other (income) expense, net

     

    (162

    )

    (27

    )

    58

     

    31

     

     

    (193

    )

    Income Before Taxes

     

    4,090

     

    (679

    )

    (279

    )

    (58

    )

    (1,016

    )

     

    5,106

     

    Income Tax Provision (Benefit)

     

    929

     

    (129

    )

    (3

    )

    (46

    )

    (3

    )

    (13

    )

    (3

    )

    (188

    )

     

    1,117

     

    Net Income

     

    3,161

     

    (550

    )

    (233

    )

    (45

    )

    (828

    )

     

    3,989

     

    Net Income Attributable to Merck & Co., Inc.

     

    3,157

    (550

    )

    (233

    )

    (45

    )

    (828

    )

     

    3,985

     

    Earnings per Common Share Assuming Dilution

    $

    1.24

     

    (0.22

    )

    (0.09

    )

    (0.02

    )

    (0.33

    )

    $

    1.57

     

     
    Tax Rate

     

    22.7

    %

     

    21.9

    %

     
    Sep YTD
    Cost of sales

    $

    11,365

     

    1,708

     

    374

     

    2,082

     

    $

    9,283

     

    Selling, general and administrative

     

    7,952

     

    88

     

    67

     

    155

     

     

    7,797

     

    Research and development

     

    13,354

     

    60

     

    2

     

    62

     

     

    13,292

     

    Restructuring costs

     

    258

     

    258

     

    258

     

     

    –

     

    Other (income) expense, net

     

    (151

    )

    (48

    )

    (107

    )

    (155

    )

     

    4

     

    Income Before Taxes

     

    15,766

     

    (1,808

    )

    (701

    )

    107

     

    (2,402

    )

     

    18,168

     

    Income Tax Provision (Benefit)

     

    2,377

     

    (350

    )

    (3

    )

    (118

    )

    (3

    )

    23

     

    (3

    )

    (259

    )

    (4

    )

    (704

    )

     

    3,081

     

    Net Income

     

    13,389

     

    (1,458

    )

    (583

    )

    84

     

    259

     

    (1,698

    )

     

    15,087

     

    Net Income Attributable to Merck & Co., Inc.

     

    13,374

    (1,458

    )

    (583

    )

    84

     

    259

     

    (1,698

    )

     

    15,072

     

    Earnings per Common Share Assuming Dilution

    $

    5.26

     

    (0.57

    )

    (0.23

    )

    0.03

     

    0.10

     

    (0.67

    )

    $

    5.93

     

     
    Tax Rate

     

    15.1

    %

     

    17.0

    %

     
    Only the line items that are affected by non-GAAP adjustments are shown.
    Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors' understanding of the company's results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management's compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
    (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets and Animal Health intangible asset impairment charges. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture.
    (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
    (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
    (4) Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.
    MERCK & CO., INC.
    FRANCHISE / KEY PRODUCT SALES
    (AMOUNTS IN MILLIONS)
    (UNAUDITED)
    Table 3
     

    2024

    2023

    3Q Sep YTD
    1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD Nom % Ex-Exch % Nom % Ex-Exch %
    TOTAL SALES (1)

    $15,775

    $16,112

    $16,657

    $48,544

    $14,487

    $15,035

    $15,962

    $45,485

    4

    7

    7

    10

    PHARMACEUTICAL

    14,006

    14,408

    14,943

    43,358

    12,721

    13,457

    14,263

    40,442

    5

    8

    7

    10

    Oncology
    Keytruda

    6,947

    7,270

    7,429

    21,646

    5,795

    6,271

    6,338

    18,403

    17

    21

    18

    22

    Alliance Revenue – Lynparza (2)

    292

    317

    337

    947

    275

    310

    299

    884

    13

    13

    7

    8

    Alliance Revenue – Lenvima (2)

    255

    249

    251

    755

    232

    242

    260

    734

    -3

    -4

    3

    3

    Welireg

    85

    126

    139

    349

    42

    50

    54

    146

    156

    157

    138

    139

    Alliance Revenue – Reblozyl (3)

    71

    90

    100

    261

    43

    47

    52

    142

    91

    91

    84

    84

    Vaccines (4)
    Gardasil/Gardasil 9

    2,249

    2,478

    2,306

    7,032

    1,972

    2,458

    2,585

    7,015

    -11

    -10

    -

    3

    ProQuad/M-M-R II/Varivax

    570

    617

    703

    1,891

    528

    582

    713

    1,823

    -1

    -1

    4

    4

    Vaxneuvance

    219

    189

    239

    647

    106

    168

    214

    488

    12

    13

    33

    34

    RotaTeq

    216

    163

    193

    572

    297

    131

    156

    584

    24

    25

    -2

    -1

    Pneumovax 23

    61

    59

    68

    188

    96

    92

    140

    327

    -51

    -51

    -42

    -40

    Hospital Acute Care
    Bridion

    440

    455

    420

    1,315

    487

    502

    424

    1,413

    -1

    -

    -7

    -6

    Prevymis

    174

    188

    208

    570

    129

    143

    157

    430

    32

    36

    33

    36

    Dificid

    73

    92

    96

    261

    65

    76

    74

    215

    31

    31

    21

    21

    Zerbaxa

    56

    62

    64

    182

    50

    54

    53

    157

    22

    25

    16

    19

    Noxafil

    56

    45

    41

    141

    60

    55

    51

    167

    -20

    -13

    -15

    -5

    Cardiovascular
    Alliance Revenue - Adempas/Verquvo (5)

    98

    106

    102

    306

    99

    68

    92

    259

    11

    11

    18

    18

    Winrevair

    70

    149

    219

    -

    -

    -

    -

    Adempas (6)

    70

    72

    72

    214

    59

    65

    65

    189

    11

    13

    13

    15

    Virology
    Lagevrio

    350

    110

    383

    843

    392

    203

    640

    1,236

    -40

    -36

    -32

    -27

    Isentress/Isentress HD

    111

    89

    102

    302

    123

    136

    119

    377

    -14

    -10

    -20

    -16

    Delstrigo

    56

    60

    65

    180

    44

    50

    54

    148

    21

    25

    22

    26

    Pifeltro

    42

    39

    42

    123

    34

    38

    37

    109

    14

    15

    13

    14

    Neuroscience
    Belsomra

    46

    53

    78

    177

    56

    63

    58

    176

    35

    40

    -

    7

    Immunology
    Simponi

    184

    172

    189

    545

    180

    180

    179

    539

    5

    7

    1

    2

    Remicade

    39

    35

    41

    115

    51

    48

    45

    144

    -9

    -5

    -20

    -16

    Diabetes (7)
    Januvia

    419

    405

    278

    1,102

    551

    511

    581

    1,642

    -52

    -49

    -33

    -30

    Janumet

    251

    224

    204

    679

    329

    354

    255

    937

    -20

    -13

    -28

    -23

    Other Pharmaceutical (8)

    576

    573

    644

    1,796

    626

    560

    568

    1,758

    13

    15

    2

    5

    ANIMAL HEALTH

    1,511

    1,482

    1,487

    4,480

    1,491

    1,456

    1,400

    4,347

    6

    11

    3

    7

    Livestock

    850

    837

    886

    2,573

    849

    807

    874

    2,530

    1

    7

    2

    7

    Companion Animal

    661

    645

    601

    1,907

    642

    649

    526

    1,817

    14

    17

    5

    7

    Other Revenues (9)

    258

    222

    227

    706

    275

    122

    299

    696

    -24

    -22

    2

    4

     
     
     
    Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
    (1) Only select products are shown.
    (2) Alliance Revenue represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs.
    (3) Alliance Revenue represents royalties.
    (4) Total Vaccines sales were $3,424 million, $3,656 million and $3,675 million in the first, second and third quarter of 2024, respectively, and $3,133 million, $3,557 million and $4,002 million in the first, second and third quarter of 2023, respectively.
    (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
    (6) Net product sales in Merck's marketing territories.
    (7) Total Diabetes sales were $745 million, $715 million and $592 million in the first, second and third quarter of 2024, respectively, and $950 million, $951 million and $924 million in the first, second and third quarter of 2023, respectively.
    (8) Includes Pharmaceutical products not individually shown above.
    (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $61 million, $15 million and $15 million in the first, second and third quarter of 2024, respectively, and $51 million, $3 million and $65 million in the first, second and third quarter of 2023, respectively.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241031033115/en/

    Get the next $MRK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MRK

    DatePrice TargetRatingAnalyst
    5/14/2025$84.00Buy → Neutral
    Citigroup
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    2/18/2025$128.00 → $105.00Buy → Hold
    Deutsche Bank
    2/10/2025$121.00 → $100.00Buy → Hold
    TD Cowen
    1/8/2025$110.00Buy → Hold
    Truist
    12/20/2024$136.00 → $105.00Outperform → Market Perform
    BMO Capital Markets
    12/10/2024$121.00Buy
    BofA Securities
    12/4/2024$130.00Hold → Buy
    HSBC Securities
    More analyst ratings

    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Seidman Christine E

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      7/2/25 12:08:35 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Glocer Thomas H

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      7/2/25 12:06:38 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Coe Mary Ellen

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      7/2/25 12:04:07 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Merck downgraded by Citigroup with a new price target

      Citigroup downgraded Merck from Buy to Neutral and set a new price target of $84.00

      5/14/25 8:57:17 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Merck with a new price target

      Cantor Fitzgerald initiated coverage of Merck with a rating of Neutral and set a new price target of $85.00

      4/22/25 8:01:38 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Merck from Buy to Hold and set a new price target of $105.00 from $128.00 previously

      2/18/25 7:11:01 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:09:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:04:52 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) taking place July 13-17, 2025, in Kigali, Rwanda. Merck will share new scientific findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational, novel nucleoside reverse transcriptase translocation inhibitor (NRTTI), dosed orally once monthly, in development for the prevention of HIV as pre-exposure prophylaxis (PrEP). HIV clinical data presented at IAS 202

      7/8/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

      NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE:CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medic

      7/7/25 10:01:00 AM ET
      $CGON
      $CLDI
      $MRK
      $REGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

      NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE:CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medic

      7/7/25 8:30:00 AM ET
      $CGON
      $CLDI
      $MRK
      $REGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MRK
    SEC Filings

    See more
    • SEC Form 11-K filed by Merck & Company Inc.

      11-K - Merck & Co., Inc. (0000310158) (Filer)

      6/27/25 2:16:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Merck & Company Inc.

      11-K - Merck & Co., Inc. (0000310158) (Filer)

      6/27/25 2:12:30 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Merck & Company Inc.

      11-K - Merck & Co., Inc. (0000310158) (Filer)

      6/27/25 2:08:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

      WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua

      11/14/23 5:25:00 PM ET
      $ASH
      $MRK
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

      Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver

      5/18/23 8:00:00 AM ET
      $ALLO
      $AMGN
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MRK
    Financials

    Live finance-specific insights

    See more
    • Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

      7/1/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Announces Third-Quarter 2025 Dividend

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the third quarter of 2025. Payment will be made on July 8, 2025, to shareholders of record at the close of business on June 16, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens

      5/27/25 1:24:00 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Announces First-Quarter 2025 Financial Results

      Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 1% KEYTRUDA Sales Grew 4% to $7.2 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 6% WINREVAIR Sales Were $280 Million Animal Health Sales Grew 5% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 10% GARDASIL/GARDASIL 9 Sales Declined 41% to $1.3 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 40% GAAP EPS Was $2.01; Non-GAAP EPS Was $2.22 Presented Compelling Data From a Diverse Range of Programs, Including: Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Phase

      4/24/25 6:30:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

      SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

      2/13/24 4:55:49 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

      SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

      2/9/23 10:54:48 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

      SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

      2/9/22 3:15:54 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care